Dora Markulin1, Aleksandar Vojta1, Ivana Samaržija1, Marija Gamulin2, Ivona Bečeheli3, Irena Jukić4, Čedomir Maglov4, Vlatka Zoldoš5, Aleksandra Fučić6. 1. University of Zagreb, Faculty of Science, Department of Biology, Division of Molecular Biology, Zagreb, Croatia. 2. University Hospital Centre Zagreb, Department of Oncology, Zagreb, Croatia. 3. Genos Glycoscience Research Laboratory, Zagreb, Croatia. 4. Croatian Institute of Transfusion Medicine, Zagreb, Croatia. 5. University of Zagreb, Faculty of Science, Department of Biology, Division of Molecular Biology, Zagreb, Croatia vzoldos@biol.pmf.hr afucic@imi.hr. 6. Institute for Medical Research and Occupational Health, Zagreb, Croatia vzoldos@biol.pmf.hr afucic@imi.hr.
Abstract
BACKGROUND: The RAS association domain family protein 1a (RASSF1A) is a prominent tumor suppressor gene showing altered promoter methylation in testicular germ cell tumors (TGCT). RASSF1A promoter hypermethylation might represent an early event in TGCT tumorigenesis. We investigated whether the RASSF1A promoter methylation in peripheral blood of TGCT patients can be associated with testicular cancer risk. MATERIALS AND METHODS: Following a meta-analysis, we performed a cohort study including 32 testicular cancer patients and 32 healthy controls. Promoter methylation of the RASSF1A and O6-methylguanine-DNA-methyltransferase (MGMT) genes was analyzed using bisulfite pyrosequencing of DNA from peripheral blood. RESULTS: Meta-analysis showed an odds ratio (OR) of 7.69 for RASSF1A promoter methylation as a risk factor for TGCT. Cohort study found altered methylation of the RASSF1A promoter in blood of TGCT patients. Methylation was higher in TGCT patients before BEP chemotherapy. CONCLUSION: The meta-analysis indicates a role of the RASSF1A promoter hypermethylation from peripheral blood in TCGT. We confirmed that finding in our cohort study, which represents the first report of changed RASSF1A promoter methylation in peripheral blood TGCT. Copyright
BACKGROUND: The RAS association domain family protein 1a (RASSF1A) is a prominent tumor suppressor gene showing altered promoter methylation in testicular germ cell tumors (TGCT). RASSF1A promoter hypermethylation might represent an early event in TGCT tumorigenesis. We investigated whether the RASSF1A promoter methylation in peripheral blood of TGCT patients can be associated with testicular cancer risk. MATERIALS AND METHODS: Following a meta-analysis, we performed a cohort study including 32 testicular cancerpatients and 32 healthy controls. Promoter methylation of the RASSF1A and O6-methylguanine-DNA-methyltransferase (MGMT) genes was analyzed using bisulfite pyrosequencing of DNA from peripheral blood. RESULTS: Meta-analysis showed an odds ratio (OR) of 7.69 for RASSF1A promoter methylation as a risk factor for TGCT. Cohort study found altered methylation of the RASSF1A promoter in blood of TGCT patients. Methylation was higher in TGCT patients before BEP chemotherapy. CONCLUSION: The meta-analysis indicates a role of the RASSF1A promoter hypermethylation from peripheral blood in TCGT. We confirmed that finding in our cohort study, which represents the first report of changed RASSF1A promoter methylation in peripheral blood TGCT. Copyright
Authors: B Smith-Sørensen; G E Lind; R I Skotheim; S D Fosså; Ø Fodstad; A-E Stenwig; K S Jakobsen; R A Lothe Journal: Oncogene Date: 2002-12-12 Impact factor: 9.867
Authors: Natalie S Shenker; Silvia Polidoro; Karin van Veldhoven; Carlotta Sacerdote; Fulvio Ricceri; Mark A Birrell; Maria G Belvisi; Robert Brown; Paolo Vineis; James M Flanagan Journal: Hum Mol Genet Date: 2012-11-21 Impact factor: 6.150
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Mansour S Al-Moundhri; Maryam Al-Nabhani; Letizia Tarantini; Andrea Baccarelli; Jennifer A Rusiecki Journal: PLoS One Date: 2010-12-23 Impact factor: 3.240
Authors: Sanjay Koul; James M McKiernan; Gopeshwar Narayan; Jane Houldsworth; Jennifer Bacik; Deborah L Dobrzynski; Adel M Assaad; Mahesh Mansukhani; Victor E Reuter; George J Bosl; Raju S K Chaganti; Vundavalli V V S Murty Journal: Mol Cancer Date: 2004-05-18 Impact factor: 27.401
Authors: Nicolas Chevalier; Charlotte Hinault; Stephan Clavel; Rachel Paul-Bellon; Patrick Fenichel Journal: Front Endocrinol (Lausanne) Date: 2021-01-26 Impact factor: 5.555